References
Mantovani G, Spada A. Mutations in the Gs alpha gene causing hormone resistance. Best Prac Res Clin Endocr Metab. 2006;20:501–513.
“Online Mendelian Inheritance in Man (OMIM), a knowledgebase of human genes and genetic disorders”. Nucleic Acids Research 33(Database issue): D514–D517. Available from: http://en.wikipedia.org/wiki/OMIM. Accessed July 19, 2011
Mariot V, Maupetit-Mehouas S, Sinding C, Kottler ML, Linglart A. A maternal epimutation of GNAS leads to Albright osteodystrophy and parathyroid hormone resistance. J Clin Endocr Metab. 2008;93:661–665.
Levine MA, Downs RW Jr, Moses AM, Breslau NA, Marx SJ, Lasker RD, et al. Resistance to multiple hormones in patients with pseudohypoparathyroidism. Association with deficient activity of guanine nucleotide regulatory protein. Am J Med. 1983;74:545–556.
Heinsimer JA, Davies AO, Downs RW, Levine MA, Spiegel AM, Drezner MK, et al. Impaired formation of beta-adrenergic receptor-nucleotide regulatory protein complexes in pseudohypoparathyroidism. J Clin Invest. 1984;73:1335–1343.
References
Nakanishi K and Yoshikawa N. Immunoglobulin A nephropathy. In: Avner ED, Harmon WE, Niaudet P, Yoshikawa N eds. Pediatric Nephrology 6th ed. Springer-Verlag Berlin Heidelberg; 2009. p.757–781.
Motoyama O, Kojima Y, Ohara A, Tsukimoto I, Ishikawa Y, Iitaka K. IgA nephropathy associated with leukemia and lymphoma: report of two cases. Clin Exp Nephrol. 2008;12: 140–143.
Churg J, Bernstein J, Glassock R. In: Renal disease: classification and atlas of glomerular diseases 2nd ed. Tokyo: Igaku-Shion Medical Publishers 1995. p.86–88.
Floege J and Ostendorf T. Cytokines and Growth factors. Lai KN ed. Recent advances in IgA nephropathy. World Scientific Publishing Co. Pte. Ltd: Singapore; 2009: p.243–266.
Nelson PJ and Shankl SJ. Therapeutics in renal disease: The road ahead for antiproliferative targets. Nephron Exp Nephrol. 2006;103:6–15.
Noris M and Remuzzi G, editor. IgA nephropathy: A stem cell disease? Kidney Int. 1999;56:1964–1966.
Wiercinski R, Zoch-Zwierz W, Stasiak-Barmuta A, Wasilewska A, Tomaszewska B, Winiecka W. Assessment of selected adhesion molecules and lymphocyte subpopulations in children with IgA nephropathy. Annales Academiae Medicae Bialostocensis. 2004;49: 106–110.
Yoshikawa N, Ito H, Nakamura H. Prognostic indicators in childhood IgA nephropathy. Nephron. 1992;60:60–67.
Hu SL, Colvin GA, Rifai A, Suzuki H, Novak J, Esparza A, et al. Glomerulonephritis after hematopoietic stem transplant: IgA nephropathy with increased excretion of dn IgA1. Nephrol Dial Transplant. 2010;25:1708–1713.
Iwata Y, Wada T, Uchiyama A, Miwa A, Nakaya I, Tohyama T, et al. Remission of IgA nephropathy after allogeneic peripheral blood stem cell transplantation followed by immunosuppression for acute lymphocytic leukemia. Intern Med. 2006;45:1291–1295.
References
Gorlin RJ, Jue KL, Jacobsen U, Goldschmidt E. Oculoauriculovertebral dysplasia. J Pediatr. 1963;63:991–999.
Gorlin RJ, Cohen Jr MM, Hennekam RCM. Branchial arch and oro-acral disorders. In: Syndromes of the head and neck, 4th ed. New York: Oxford University Press; 2001. p. 790–797.
Cohen Jr MM, Rollnick BR, Kaye CI. Oculoauriculovertebral spectrum: an updated critique. Cleft Palate J. 1989;26:276–286.
Rollnick BR, Kaye CI, Nagatoshi K, Hauck W, Martin AO. Oculoauriculovertebral dysplasia and variants: phenotypic characteristics of 294 patients. Am J Med Genet. 1987;26:361–375.
Pillay K, Matthews LS, Wainwright HC. Facio-auriculovertebral sequence in association with DiGeorge sequence, Rokitansky sequence, and Dandy Walker malformation: case repuoiort. Pediatr Dev Pathol. 2003;6:355–360.
Sadler TW, Langeman J. Craniofacial development. In: Langeman’s Essential Medical Embryology, Vol 1. Baltimore: Lippincott Williams and Wilkins; 2005. p. 87–102.
References
Packman C. Hemolytic anemia due to warm autoantibodies. Blood Rev. 2008;22:17–31.
Miloh T, Arnon R, Roman E, Hurlet A, Kerkar N, Wistinghausen B. Autoimmune hemolytic anemia and idiopathic thrombocytopenic purpura in pediatric solid organ transplant recipients, report of five cases and review of the literature. Pediatr Transplant. 2011;15:870–878.
Quartier P, Brethon B, Philippet P, Landman-Parker J, Le Deist F, Fischer A. Treatment of childhood autoimmune haemolytic anemia with rituximab. The Lancet. 2001;358:1511–1513.
Zecca M, Nobili B, Ramenghi U, Perrotta S, Amendola G, Rosito P, et al. Rituximab for the treatment of autoimmune refractory hemolytic anemia in children. Blood. 2003;101:3857–3861.
Giulino L, Bussel J, Neufeld E, Pediatric and Platelet Immunology Committees of the TMH Clinical Trial Network. Treatment with rituximab in benign and malignant hematologic disorders in children. J Pediatr. 2007;150:338–344.
Kim J, Thrasher J, Jones A, Davies EG, Cale CM. Rituximab for the treatment of autoimmune cytopenias in children with immune deficiency. Br J Haematol. 2007;138:94–96.
Svahn J, Fioredda F, Calvillo M, Molinari AC, Micalizzi C, Banov L, et al. Rituximab-based immunosuppression for autoimmune haemolytic anaemia in infants. Br J Haematol. 2009;145:96–100.
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Joshi, R., Kapdi, M., Udani, A. et al. Case Reports. Indian Pediatr 49, 667–674 (2012). https://doi.org/10.1007/s13312-012-0123-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13312-012-0123-4